中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
2026-06-22
Tsoi Hoi Shan Attended Novo Nordisk Roundtable to Discuss the Global Impact of Chinese Innovation
Learn More
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
Learn More
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
Learn More
All News
Select Year
2026
2025
2024
Revenue Reaches RMB 13.759 Billion! TUL announced Full-Year 2024 financial results
2025-03-25
TUL Enters into An Exclusive Licensing Agreement with Novo Nordisk
2025-03-24
TUL’s Polyvinyl Alcohol Eye Drops Approved for Market Launch
2025-03-21
TUL’s Liraglutide Injection Approved for Market Launch
2025-03-21
Chairman Tsoi Hoi Shan Visits Neixiang, Henan for Industrial Cooperation Inspection
2025-03-20
The Freeze-dried Powder Injection and Sterile Bulk Medicine Production Lines of The United Animal Healthcare (Inner Mongolia) Co., Ltd. Passes Veterinary Drug GMP Certification
2025-03-19
TUL’s Amoxil Ranks Among the “2024–2025 Best-Selling Products in China’s Pharmaceutical Retail Market” and Wins the “2024–2025 CPHCF Award”
2025-03-17
Zhuhai United Laboratories Co., Ltd. Passes Brazilian Official GMP Inspection
2025-03-17
TUL Debuts at VIV Asia 2025, Embarking on a New Global Journey
2025-03-15
Prev
1
...
8
9
10
11
12
...
17
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
